Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare ...
Medgadget (blog)
Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

and more »

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
Dove Medical Press
... the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion ...


Smart phone ophthalmoscope may improve the accuracy of fundal exams by medical students
MD Linx (press release)
They performed 200 fundal examinations on the eyes of 10 mannequins featuring 5 unique fundal images (optic atrophy, dry age-related macular degeneration, central retinal vein occlusion, papilledema, and pre-proliferative diabetic retinopathy). The ...


Phys.Org

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography
Phys.Org
... diabetic retinopathy, central retinal vein occlusion, sickle cell retinopathy, toxic an autoimmune retinopathies, retinal detachment, and other ocular disorders. To be properly diagnosed and treated (especially when a cataract compromises ...


Nasdaq

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD
Nasdaq
Eylea is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and ...

and more »

Retinal Vein Occlusion Market to Perceive Superior Growth with CAGR of 11.2% | By Types Branch Retinal Artery ...
Digital Journal
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...


Relationship between vascular endothelial growth factor and macular edema in retinal vein branch obstruction
Dove Medical Press
Purpose: Vascular endothelial growth factor (VEGF) plays an important role in branch retinal vein occlusion (BRVO) with cystoid macular edema (CME). Monitoring changes in VEGF is crucial for evaluating treatment but requires vitreous or aqueous humor ...


MD Magazine

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases
MD Magazine
New intravitreal biosimilar anti-vascular endothelial growth factor (VEGF) therapies bevacizumab and ranibizumab have been proven to be effective and safe for nearly a half-dozen retina conditions, according to new data presented at the American ...


Nasdaq

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Nasdaq
... neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion, and macular edema following branch retinal ...
Intl Fcstone Inc. Buys Shares of 674 Regeneron Pharmaceuticals Inc (REGN)Fairfield Current

all 14 news articles »

Taiwan News

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a ...
Taiwan News
Patients in the PDS 100 mg/mL arm achieved similar gains in Best Corrected Visual Acuity (BCVA) and similar reductions in central retina thickness compared to patients receiving monthly ranibizumab 0.5 mg injections. The PDS is ... Lucentis is FDA ...

and more »

MD Magazine

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2
MD Magazine
... the examination was the second analysis to the baseline to 6 months data originally collected in 2017, which included 362 patients with macular edema due to either central or hemispheric retinal vein occlusion, randomized to either bevacizumab (n ...


Fairfield Current

Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Nasdaq
... an intravitreal anti-VEGF agent may result in earlier, superior visual acuity outcome as compared to monthly injections of an intravitreal anti-VEGF alone in newly diagnosed branch retinal vein occlusion ("BRVO") and central retinal vein occlusion ...
Clearside Biomedical Inc. (CLSD) CEO Daniel White on Q2 2018 Results - Earnings Call TranscriptSeeking Alpha

all 12 news articles »

Fairfield Current

Massachusetts Financial Services Co. MA Has $61.08 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ ...
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 88 news articles »

MD Magazine

DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
MD Magazine
The presence of disorganization of inner retinal layers (DRIL) at baseline, as well as changes in DRIL burden during treatment with anti-vascular endothelial growth factor (anti-VEGF), can be a prognostic indicator for improvement in Early Treatment ...


Nisa Investment Advisors LLC Has $6.40 Million Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


XNewsPress

Regeneron Pharmaceuticals (REGN) Releases Earnings Results
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
BeiGene launches late-stage study of tislelizumab in first-line lung cancerSeeking Alpha
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Replimune set for $101M IPOSeeking Alpha
Schaeffers Research
all 74 news articles »

Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Massachusetts Financial Services Co. MA
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Replimune set for $101M IPOSeeking Alpha

all 102 news articles »

Global Retinal Vein Occlusion Therapeutics Market 2018 | Industry Outlook Report 2012 & Future Forecast Till 2023
managementjournal24.com
The “Global Retinal Vein Occlusion Therapeutics Market Analysis Report 2018” is a pervasive research study, which provides current as well as upcoming technical and financial details of the Retinal Vein Occlusion Therapeutics industry, that would help ...


Global Retinal Vein Occlusion Therapeutics Market 2018 | Status( 2013-2017) and Forecast(2018-2025)
Energy News
Market study report Titled Global Retinal Vein Occlusion Therapeutics Market 2018 Industry Research Report recently published on Market.biz is the key document for industries/clients to understand current global competitive market status. ... America ...

and more »

Regeneron Pharmaceuticals (REGN) Set to Announce Quarterly Earnings on Wednesday
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Retinal Vein Occlusion Therapeutics Market Facts, Figures and Analytical Insights, Forecast 2015 – 2021
364Analyze.com (press release)
The RVO is mainly of two types based on the anatomy of the vein occlusion. The two types are branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The BRVO occurs when the vein in the distal retinal system gets occluded ...


Fairfield Current

Head-To-Head Review: AbbVie (ABBV) versus Clearside Biomedical (CLSD)
Fairfield Current
... enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients ...

and more »

News Oracle

Regeneron Pharmaceuticals Inc (REGN) Director Sells $720000.00 in Stock
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 122 news articles »

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF ...

and more »

Stonebridge Capital Management Inc. Has $902000 Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


WPLG Local 10

Vasular condition leads to sudden sight loss
WPLG Local 10
Burgess was diagnosed with central retinal vein occlusion, or CRVO, a condition that causes a clot to form in the eye, leading to damaging pressure. "It was like someone threw a tomato at my eye," Burgess said. Cardiologist Dr. Adam Splaver said CRVO ...


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Amalgamated Bank Purchases 813 Shares of Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »
» Load more